Gefitinib, a first generation small-molecule epidermal growth factor receptor (EGFR) inhibitor, is highly active in NSCLC patients harboring EGFR-activating mutations including exon 19 deletion (E746-A750) mutation, exon 21 L858R mutation, and EGFR amplification [3–5]. Here, EGFR is linked to non-small cell lung carcinoma.